Roche and Hansoh Pharma's Tam-Peli Demonstrates Significant Overall Survival Benefit in Relapsed Small-Cell Lung Cancer

Roche's collaborator MediLink Therapeutics and Hansoh Pharmaceutical Group announced positive interim results from the Phase III TAISHAN-302 (ARTEMIS-008) trial. The study showed that Tam-Peli (tambotatug pelitecan, also known as Risvutatug Rezetecan or HS-20093), an investigational antibody-drug conjugate, significantly improved overall survival in Chinese patients with relapsed small-cell lung cancer. China's National Medical Products Administration (NMPA) has accepted the New Drug Application for filing.